Radiation Techniques in the Treatment of Lung Cancer
Multidisciplinary evaluations of patients with non-small cell lung cancer (NSCLC) should include radiation oncologists, because radiation therapy (RT) has a potential role in all stages of NSCLC. The NCCN Guidelines® recommend consolidation immunotherapy after concurrent chemoradiation for patients with unresectable stage III NSCLC. Some oncologists may not be aware of the nuances of treating patients with chemoradiation followed by immunotherapy including the need to assess for adverse events. The NCCN Guidelines Panel for Non-Small Cell Lung Cancer recently revised the normal tissue dose-volume constraints for conventionally fractionated RT to help decrease potential toxicity to normal tissues when using concurrent chemoradiotherapy.
This educational program is designed to meet the educational needs of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, pharmacists, physician assistants, and other relevant health care professionals who manage the care of patients with lung cancer.
Following this activity, participants should be able to:
- Describe the role of stereotactic ablative radiation therapy in patients with early-stage non-small cell lung cancer.
- Recommend appropriate consolidation therapy in patients with stage III non-small cell lung cancer.
- Recognize how to decrease toxicity in patients with non-small cell lung cancer receiving concurrent chemoradiation.
Russell Hales, MD
The Sidney Kimmel Comprehensive Cancer Center an Johns Hopkins
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Russell Hales, MD
Genentech, Inc.: Grant/Research Support
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson;
Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair;
Kathy Ann Smith, CHCP
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer L. Burns, BS; Susan D. Darlow, PhD; Miranda Hughes, PhD; Alyse Johnson-Chilla;
Ann Karosas, RPh, BCOP; Rashmi Kumar, PhD; Jillian Scavone, PhD (employed by NCCN until 7.26.19)
The NCCN Clinical staff listed below discloses the following relevant financial relationships:
Griselda Zuccarino-Catania, PhD
Janssen Pharmaceutica Products, LP: Spouse Salary
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 0.68 contact hours.
NCCN designates this knowledge-based continuing education activity for 0.75 contact hours (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-107-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 12/17/2020. PAs should only claim credit commensurate with the extent of their participation.
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.68 ANCC contact hours
- 0.75 Participation
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing